<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78848">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01804946</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-ER-001</org_study_id>
    <nct_id>NCT01804946</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza</brief_title>
  <official_title>Multicentre Open Label Comparative Parallel-group Randomized Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  to assess clinical efficiency of Ergoferon for treatment of influenza

        -  to assess safety of Ergoferon for treatment of influenza

        -  to compare efficiency of Ergoferon and Tamiflu for treatment of influenza
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of patients whose body temperature normalized (no more than 37.0ºС)</measure>
    <time_frame>up to 5 days of the treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients whose influenza clinical manifestations were arrested</measure>
    <time_frame>on the day 7 of the observation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Intensity of influenza clinical manifestations (body temperature, intoxication signs, catarrh symptoms in scores)</measure>
    <time_frame>on days 1, 3 and 7 of the observation</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Ergoferon (1 tablet 3 times a day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet per 1 intake: on day 1 of the treatment 8 tablets (1 tablet every 30 minutes for the first 2 hours, then 1 tablet 3 times a day with equal intervals starting on the same day. From day 2 to day 5 1 tablet TID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir(Tamiflu): 75 mg two times a day.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergoferon</intervention_name>
    <description>Safety and Efficiency of Ergoferon in treatment of Influenza</description>
    <arm_group_label>Ergoferon (1 tablet 3 times a day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir(Tamiflu)</intervention_name>
    <description>Safety and Efficiency in treatment of Influenza</description>
    <arm_group_label>Oseltamivir(Tamiflu): 75 mg two times a day.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of both sexes aged from 18 to 60 inclusively.

          2. Patients with body temperature &gt;37,8°C at the moment of examination by the doctor;
             with at least one catarrh symptom (cough, rhinitis, sore throat) and one intoxication
             symptom (myalgia, fever/hyperhidrosis, malaise, weakness, headache) during seasonal
             influenza morbidity.

          3. Diagnosed influenza confirmed by express diagnostics (presence of antigens of
             influenza virus in nasal passages epithelium and proved by QuickVue immunological
             test).

          4. The possibility to start therapy within 24 hours after the onset of the first
             influenza symptoms.

          5. Signed Informed Consent form for participation in the study.

        Exclusion Criteria:

          1. Patients aged below 18 years and above 60 years.

          2. Suspected invasive bacterial infection or presence of severe disease requiring use of
             antibacterial drugs (including sulfanilamides).

          3. Vaccination against influenza prior to epidemic season onset.

          4. Medical history of polyvalent allergy.

          5. Allergy/ intolerance to any of the components of  medications used in the treatment.

          6. Exacerbation or decompensation of chronic diseases affecting the patient's ability to
             participate in the clinical trial.

          7. Chronic renal insufficiency.

          8. Intake of medicines listed in the section &quot;Prohibited concomitant treatment&quot; for  15
             days prior to the inclusion in the trial.

          9. Pregnancy, breast feeding, unwillingness to keeping to contraception method during
             the study.

         10. Drug addiction,  alcohol usage in the amount over 2 units of alcohol per day.

         11. Patients, who from investigator's point o view, will fail to comply with the
             observation requirements of the trial or with the intake regimen of the investigated
             medicines.

         12. Participation in other clinical trials in the course of 1 month prior to the
             inclusion in the trial.

         13. The patient is related to the research personnel of the investigative site, who are
             directly involved in the trial or are the immediate relative of the reseacher. The
             immediate relatives includes husband / wife, parents, children, brothers (or
             sisters), regardless of whether they are natural or adopted.

         14. The patient works for OOO &quot;NPF &quot;Materia Medica Holding&quot; (i.e. is the company's
             employee, temporary contract worker or designated official responsible for carrying
             out the research) or the immediate relative.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikhail Putilovskiy, MD</last_name>
    <phone>+74957836804</phone>
    <phone_ext>302</phone_ext>
    <email>PutilovskiyMA@materiamedica.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Federal Budgetary Institution of Science &quot;Moscow Scientific Research Institute of Epidemiology and Microbiology named after G.N. Gabrichevskiy&quot; of Federal Service on Surveillance in Consumers Protection and Welfare</name>
      <address>
        <city>Moscow</city>
        <zip>125212</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Scientific Research Institute for Vaccines and Serum named after I.I.Mechnikov&quot; of Russian Academy of Medical Science</name>
      <address>
        <city>Moscow</city>
        <zip>105064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Polyclinic № 3&quot; of Affairs Management Department of the President of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot;The Russian National Research Medical University named after N.I. Pirogov&quot; of Ministry of Health and Social Development of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Federal State Health Care Institution &quot;Clinical Hospital №83&quot; of Federal Biomedical Agency</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Municipal Health Care Institution &quot;Podolsk City Clinical Hospital №3&quot;</name>
      <address>
        <city>Podolsk</city>
        <zip>142105</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot;Smolensk State Medical Academy&quot; of Ministry of Health and Social Development of Russian Federation</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Health Care Institution &quot;Сity Polyclinic № 117&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Alpenidze</last_name>
    </contact>
    <investigator>
      <last_name>Diana Alpenidze</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Health Care Institution &quot;All-Russian center for Emergency and Radiological Medicine named after A.M. Nikiforov&quot; of Ministry of Russian Federation on Civil Defence, Emergencies and Relief of the Consequencies of Natural Disasters</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Health Care Institution &quot;City Polyclinic №106&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198328</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danila Chijov</last_name>
    </contact>
    <investigator>
      <last_name>Danila Chijov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budgetary Health Care Institution of the Vladimir Region &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Voronezh State Academy named after N.N. Burdenko&quot; of Ministry of Health and Social Development of Russian Federation</name>
      <address>
        <city>Voronezh</city>
        <zip>394036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot;Yaroslavl State Medical Academy&quot; of Ministry of Health and Social Development of Russian Federation</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
